APA

Aranapakam V., Davis J. M., Grosu G. T., Baker J., Ellingboe J., Zask A., Levin J. I., Sandanayaka V. P., Du M., Skotnicki J. S., DiJoseph J. F., Sung A., Sharr M. A., Killar L. M., Walter T., Jin G., Cowling R., Tillett J., Zhao W., McDevitt J. & Xu Z. B. (20030711). Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. : Journal of medicinal chemistry.

Chicago

Aranapakam Venkatesan, Davis Jamie M, Grosu George T, Baker Jannie, Ellingboe John, Zask Arie, Levin Jeremy I, Sandanayaka Vincent P, Du Mila, Skotnicki Jerauld S, DiJoseph John F, Sung Amy, Sharr Michele A, Killar Loran M, Walter Thomas, Jin Guixian, Cowling Rebecca, Tillett Jeff, Zhao Weiguang, McDevitt Joseph and Xu Zhang Bao. 20030711. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. : Journal of medicinal chemistry.

Harvard

Aranapakam V., Davis J. M., Grosu G. T., Baker J., Ellingboe J., Zask A., Levin J. I., Sandanayaka V. P., Du M., Skotnicki J. S., DiJoseph J. F., Sung A., Sharr M. A., Killar L. M., Walter T., Jin G., Cowling R., Tillett J., Zhao W., McDevitt J. and Xu Z. B. (20030711). Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. : Journal of medicinal chemistry.

MLA

Aranapakam Venkatesan, Davis Jamie M, Grosu George T, Baker Jannie, Ellingboe John, Zask Arie, Levin Jeremy I, Sandanayaka Vincent P, Du Mila, Skotnicki Jerauld S, DiJoseph John F, Sung Amy, Sharr Michele A, Killar Loran M, Walter Thomas, Jin Guixian, Cowling Rebecca, Tillett Jeff, Zhao Weiguang, McDevitt Joseph and Xu Zhang Bao. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. : Journal of medicinal chemistry. 20030711.